No abstract

No abstract

Coffee is the second most popular drink worldwide, and it has various components with antioxidant and antitumor properties. Due to its chemical composition, it could act as an antitumor substance in the gastrointestinal tract. The objective of this study was to explore the relationship between coffee consumption and the incidence/mortality of stomach cancer in the highest-consuming countries. An ecological study using Spearman's correlation coefficient was performed. The WorldAtlas's dataset of coffee consumption and the incidence/mortality rates database of the International Agency for Research were used as sources of information. A total of 25 countries were entered to the study. There was an inverse linear correlation between coffee consumption in kg per person per year and estimated age-adjusted incidence (r = 0.5984, p = 0.0016) and mortality (r = 0.5877, p = 0.0020) of stomach cancer. Coffee may potentially have beneficial effects on the incidence and mortality of stomach cancer, as supported by the data from each country analyzed.

To describe our experience upon developing and implementing a hospital-based cancer registry (HBCR) in a quaternary-level of care private non-pro t academic medical center in Cali, Colombia. MethodsHBCRs capture, in a given institution, every single patient with a con rmed malignancy. In this study, all cases evaluated between 2014 and 2018 were included in the HBCR. In compliance with the International Agency for Research on Cancer (IARC) recommendations, cases were classi ed as analytic or nonanalytic. Data derived from an exhaustive selection of patients was stored in a computing platform owned by the institution, meeting the 2016 Facility Oncology Registry Data Standards (FORDS) recommendations. Quality control was performed by evaluating comparability, timeliness, validity, and completeness. ResultsA total of 24,405 new cases were registered between 2014 and 2018, from which 4,253 (17.4%) died. Among all cases, based on the anatomic location, most common malignancies were breast (n = 1,554), thyroid (n = 1,346), hematolymphoid (n = 1,251), prostatic (n = 805), and colorectal (n = 624). The behavior of the incidence was consistent with an incremental trend. ConclusionUpon implementing the HBCR, major challenges were identi ed (i.e. a precise de nition of cases, the development of processes for capturing new cases, a standardized data collection strategy, and carryingout an appropriate patient follow-up). Based on our experience, the success of an HBCR largely relies on the interest from the institution, the engagement of stakeholders and nancial support, that is, it depends on the adequate access over time to funding, technological, and sta ng resources.There are mainly two types of cancer registries. One that measures the impact of the disease in speci c demographics, known as Population-Based Cancer Registry (PBCR) [3]. On the other hand, Hospital-Based Cancer Registries (HBCRs), mainly evaluate the burden of the disease and the quality of healthcare services, as well as the organizational and administrative support from the institution [4,5]. Although PBCRs are a valuable source of information, in Colombia, these do not often include clinical data, thus limiting the assessment of important variables, such as accuracy of diagnosis, quality of treatment, demand for health services, among others [6].Although the bene ts of implementing an HBCR have been evidenced [7, 8], its success over time requires the interest from the institution, the engagement of stakeholders and nancial support. For instance, in Colombia, the National Cancer Institute (INC by its Spanish acronym: Instituto Nacional de Cancerología) is the only institution with an HBCR that has published data [9,10]. The purpose of this study is to describe our experience upon developing and implementing the Institutional Cancer Registry (RIC by its Spanish acronym: Registro Institucional de Cáncer) in Fundación Valle del Lili (FVL). Our methodology may serve as a role model for other health centers in the country, Latin America and the Caribbean. The ...

Background: Multiple primary malignant neoplasms are not frequent but are increasing in incidence. Some of them are associated with genetic syndromes such as von Hippel-Lindau syndrome and Li-Fraumeni syndrome. Dedifferentiated liposarcoma is one of the rarest soft tissue tumors, and clear cell renal carcinoma is the most frequent kidney cancer. The concomitant presence of these tumors is extremely rare; however, some cases have been reported, none of them presenting with liposarcoma of the limbs. We report an interesting case of a patient with synchronous multiple primary tumors presenting with a very rare liposarcoma associated with renal cell carcinoma (a very rare association). A review of the literature and a collection of similar cases published previously are also provided. Case presentation: We report a case of a 62-year-old Hispanic man who presented to our institution with a left thigh mass compatible with dedifferentiated liposarcoma synchronous with metastatic clear cell renal carcinoma. Multiple treatment lines were provided with no response, with a further metastatic transformation. Genetic analysis by liquid biopsy showed some mutations that were not susceptible to targeted therapy. At the time of this report, the patient is undergoing palliative care because his nonresponsive metastatic disease persists. Conclusions: We present the first reported case of clear cell renal carcinoma synchronous with dedifferentiated liposarcoma of a limb. The association between renal cell carcinoma and dedifferentiated liposarcoma is unusual, and there are few reports of this presentation in the literature. More research about these tumors along with genetic tests needs to be performed to seek a better understanding of the fundamental basis of this rare association.